The drug industry doesn’t pack the lobbying punch it once did, and one sign is something rare in the capital today—a dose of bipartisanship.

Sen. Chuck Grassley (R., Iowa) joined Sen. Ron Wyden (D., Ore.) to write a bill last July to regulate prescription-drug prices, an idea the industry has bottled up since the 1960s. Sen. John Cornyn (R., Texas) with Sen. Richard Blumenthal (D., Conn.) sponsored a bill in May to block drug companies from using patent laws to delay lower-priced drugs….

Read the full article from The Wall Street Journal